Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.71 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.71 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.53 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15652145 | 0.84 | L3MBTL1 (0.63) | L3MBTL1MBTD1KMT2AHTR7SFRP1 | |
| SCHEMBL18506938 | 0.84 | L3MBTL1 (0.52) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 | |
| SCHEMBL10854490 | 0.83 | SIGMAR1 (0.83) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 | |
| SCHEMBL1636286 | 0.83 | L3MBTL1 (0.74) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 | |
| SCHEMBL3322160 | 0.83 | L3MBTL1 (0.74) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 | |
| SCHEMBL23682795 | 0.83 | L3MBTL1 (1.00) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 | |
| SCHEMBL6034608 | 0.83 | SIGMAR1 (0.83) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 | |
| SCHEMBL5198457 | 0.82 | HTR7 (0.74) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 | |
| SCHEMBL14039394 | 0.82 | L3MBTL1 (0.97) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 | |
| SCHEMBL3327029 | 0.82 | L3MBTL1 (0.72) | L3MBTL1MBTD1SIGMAR1KMT2AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267133-A1 | Pyrazolopyrimidines as kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267133-A1 | Pyrazolopyrimidines as kinase inhibitors | BRAF, MAP3K2, MAP3K19 | L3MBTL1 2169/4885MBTD1 1903/4885SIGMAR1 3492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.